GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 57 filers reported holding GRITSTONE ONCOLOGY INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,776 | -70.4% | 49,870 | -58.3% | 0.00% | – |
| Q2 2022 | $290,000 | -13.2% | 119,645 | +47.6% | 0.00% | – |
| Q1 2022 | $334,000 | -48.0% | 81,064 | +62.3% | 0.00% | – |
| Q4 2021 | $642,000 | -70.1% | 49,932 | -74.9% | 0.00% | -100.0% |
| Q3 2021 | $2,149,000 | -71.2% | 198,924 | -75.6% | 0.00% | -75.0% |
| Q2 2021 | $7,451,000 | +3644.2% | 816,059 | +3772.2% | 0.00% | – |
| Q1 2021 | $199,000 | -61.5% | 21,075 | -84.0% | 0.00% | – |
| Q4 2020 | $517,000 | +27.3% | 131,363 | -14.2% | 0.00% | – |
| Q3 2020 | $406,000 | -51.1% | 153,086 | +22.3% | 0.00% | -100.0% |
| Q2 2020 | $831,000 | +151.1% | 125,167 | +120.2% | 0.00% | – |
| Q1 2020 | $331,000 | -35.5% | 56,849 | -0.9% | 0.00% | – |
| Q4 2019 | $513,000 | +27.6% | 57,357 | +22.7% | 0.00% | – |
| Q3 2019 | $402,000 | -7.2% | 46,748 | +19.7% | 0.00% | – |
| Q2 2019 | $433,000 | +13.6% | 39,070 | +36.0% | 0.00% | – |
| Q1 2019 | $381,000 | -15.0% | 28,729 | -1.1% | 0.00% | – |
| Q4 2018 | $448,000 | – | 29,056 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 4,450,638 | $41,970,000 | 8.18% |
| Copernicus Capital Management, LLC | 37,000 | $349,000 | 5.64% |
| EcoR1 Capital, LLC | 3,421,287 | $32,263,000 | 1.43% |
| Palo Alto Investors LP | 2,298,382 | $21,674,000 | 1.24% |
| AlpInvest Partners B.V. | 226,866 | $2,139,000 | 1.06% |
| Stenahm Asset Managment Ltd | 150,000 | $1,415,000 | 1.00% |
| FRAZIER MANAGEMENT LLC | 1,030,878 | $9,721,000 | 0.78% |
| BVF INC/IL | 1,861,239 | $17,551,000 | 0.66% |
| Avidity Partners Management LP | 2,122,064 | $20,011,000 | 0.55% |
| Redmile Group, LLC | 2,448,158 | $23,086,000 | 0.32% |